Heart disease: recruitment of MEF2 activity by β-blockers wards off cardiomyocyte death

Cell Death Dis. 2015 Oct 15;6(10):e1916. doi: 10.1038/cddis.2015.293.

Authors

S Hashemi^{1

2

3}, S Wales^{1

2

3}, T Miyake^{1

2

3}, J C McDermott^{1

2

3

4}

Affiliations

¹ Department of Biology, York University, Toronto, Canada.
² Muscle Health Research Centre (MHRC), York University, Toronto, Canada.
³ Centre for Research in Biomolecular Interactions (CRBI), York University, Toronto, Canada.
⁴ Centre for Research in Mass Spectrometry (CRMS), York University, Toronto, Canada.

No abstract available

MeSH terms

Adrenergic beta-Antagonists / pharmacology*
Adrenergic beta-Antagonists / therapeutic use
Apoptosis
Cardiotonic Agents / pharmacology*
Cardiotonic Agents / therapeutic use
Cell Survival
Heart Diseases / drug therapy
Heart Diseases / metabolism*
Heart Diseases / pathology
Humans
MEF2 Transcription Factors / physiology*
Myocytes, Cardiac / drug effects
Myocytes, Cardiac / physiology*

Substances

Adrenergic beta-Antagonists
Cardiotonic Agents
MEF2 Transcription Factors